Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 20 | 2023 | 551 | 1.630 |
Why?
|
| Health Care Costs | 10 | 2019 | 407 | 1.080 |
Why?
|
| Quality-Adjusted Life Years | 16 | 2021 | 128 | 0.930 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2021 | 35 | 0.830 |
Why?
|
| Rhytidoplasty | 1 | 2022 | 8 | 0.760 |
Why?
|
| Drugs, Generic | 1 | 2021 | 14 | 0.730 |
Why?
|
| Decision Support Techniques | 5 | 2019 | 309 | 0.730 |
Why?
|
| Drug Costs | 1 | 2021 | 65 | 0.700 |
Why?
|
| Wound Healing | 4 | 2019 | 476 | 0.640 |
Why?
|
| Raynaud Disease | 1 | 2018 | 4 | 0.590 |
Why?
|
| Scleroderma, Localized | 1 | 2018 | 8 | 0.590 |
Why?
|
| Skin Ulcer | 1 | 2018 | 32 | 0.580 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 27 | 0.520 |
Why?
|
| Primary Prevention | 1 | 2017 | 178 | 0.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 332 | 0.480 |
Why?
|
| Insurance Coverage | 4 | 2023 | 124 | 0.460 |
Why?
|
| Prescription Drugs | 1 | 2015 | 54 | 0.460 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 271 | 0.450 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 680 | 0.410 |
Why?
|
| Forehead | 2 | 2022 | 12 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1346 | 0.390 |
Why?
|
| Models, Economic | 5 | 2019 | 55 | 0.340 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 1540 | 0.310 |
Why?
|
| Fingers | 2 | 2019 | 67 | 0.290 |
Why?
|
| Replantation | 2 | 2019 | 56 | 0.290 |
Why?
|
| Education, Medical, Continuing | 2 | 2017 | 144 | 0.240 |
Why?
|
| Prognosis | 4 | 2019 | 5004 | 0.240 |
Why?
|
| United States | 15 | 2023 | 11619 | 0.240 |
Why?
|
| Humans | 35 | 2023 | 131930 | 0.220 |
Why?
|
| Insurance, Health | 2 | 2023 | 144 | 0.220 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 663 | 0.220 |
Why?
|
| Medicare | 4 | 2016 | 447 | 0.210 |
Why?
|
| Research Design | 2 | 2018 | 743 | 0.200 |
Why?
|
| Tissue Expansion | 1 | 2022 | 14 | 0.200 |
Why?
|
| Rhinoplasty | 1 | 2023 | 45 | 0.190 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 202 | 0.190 |
Why?
|
| Eyebrows | 1 | 2022 | 9 | 0.190 |
Why?
|
| Amputation, Traumatic | 2 | 2019 | 11 | 0.190 |
Why?
|
| Rejuvenation | 1 | 2022 | 12 | 0.190 |
Why?
|
| Skin | 2 | 2022 | 537 | 0.190 |
Why?
|
| Finger Injuries | 2 | 2019 | 23 | 0.190 |
Why?
|
| Cicatrix | 1 | 2022 | 122 | 0.180 |
Why?
|
| Ear, External | 1 | 2021 | 23 | 0.180 |
Why?
|
| Arteries | 2 | 2019 | 221 | 0.170 |
Why?
|
| Surgical Flaps | 1 | 2022 | 187 | 0.170 |
Why?
|
| Vascular Grafting | 2 | 2019 | 49 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2019 | 3710 | 0.170 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2020 | 9 | 0.170 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 6 | 0.170 |
Why?
|
| Orphan Drug Production | 1 | 2020 | 5 | 0.170 |
Why?
|
| Endoscopy | 1 | 2022 | 281 | 0.160 |
Why?
|
| Graft Survival | 2 | 2019 | 471 | 0.160 |
Why?
|
| Surgery, Plastic | 1 | 2021 | 98 | 0.160 |
Why?
|
| Leeching | 1 | 2019 | 2 | 0.150 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 79 | 0.150 |
Why?
|
| Perforator Flap | 1 | 2019 | 9 | 0.150 |
Why?
|
| Clinical Competence | 2 | 2016 | 1070 | 0.150 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2018 | 39 | 0.140 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2020 | 260 | 0.140 |
Why?
|
| Dermatologic Agents | 1 | 2018 | 30 | 0.140 |
Why?
|
| Gross Domestic Product | 1 | 2018 | 1 | 0.140 |
Why?
|
| Life Tables | 1 | 2018 | 28 | 0.140 |
Why?
|
| Upper Extremity | 1 | 2018 | 55 | 0.140 |
Why?
|
| Triterpenes | 1 | 2018 | 24 | 0.140 |
Why?
|
| Treatment Outcome | 11 | 2021 | 12996 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1294 | 0.130 |
Why?
|
| Decision Making | 3 | 2017 | 694 | 0.130 |
Why?
|
| Income | 1 | 2018 | 136 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 118 | 0.130 |
Why?
|
| Male | 14 | 2023 | 64846 | 0.130 |
Why?
|
| Nutrition Therapy | 1 | 2017 | 13 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 145 | 0.130 |
Why?
|
| Educational Measurement | 2 | 2016 | 328 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2015 | 1191 | 0.130 |
Why?
|
| Survival Rate | 2 | 2019 | 2183 | 0.130 |
Why?
|
| Certification | 1 | 2016 | 72 | 0.120 |
Why?
|
| Developing Countries | 1 | 2018 | 276 | 0.120 |
Why?
|
| Societies, Medical | 2 | 2021 | 778 | 0.120 |
Why?
|
| Choice Behavior | 2 | 2014 | 130 | 0.120 |
Why?
|
| Regeneration | 1 | 2018 | 225 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 102 | 0.120 |
Why?
|
| Female | 13 | 2021 | 70607 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 402 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2020 | 784 | 0.110 |
Why?
|
| Health Policy | 2 | 2014 | 228 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 463 | 0.110 |
Why?
|
| Malnutrition | 1 | 2017 | 161 | 0.110 |
Why?
|
| Nerve Block | 1 | 2015 | 61 | 0.110 |
Why?
|
| Anesthesiology | 1 | 2015 | 99 | 0.100 |
Why?
|
| Ischemia | 2 | 2019 | 371 | 0.100 |
Why?
|
| Ultrasonography, Interventional | 1 | 2015 | 208 | 0.100 |
Why?
|
| Global Health | 1 | 2018 | 615 | 0.100 |
Why?
|
| Sympathectomy | 1 | 2012 | 8 | 0.100 |
Why?
|
| Efficiency | 1 | 2013 | 67 | 0.100 |
Why?
|
| Health Care Rationing | 1 | 2013 | 63 | 0.100 |
Why?
|
| Patients | 1 | 2013 | 127 | 0.090 |
Why?
|
| Health Expenditures | 1 | 2013 | 114 | 0.090 |
Why?
|
| Perception | 1 | 2013 | 236 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 294 | 0.090 |
Why?
|
| Lower Extremity | 1 | 2012 | 187 | 0.080 |
Why?
|
| SEER Program | 3 | 2016 | 218 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 563 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3082 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5394 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 922 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 656 | 0.080 |
Why?
|
| Aged | 9 | 2020 | 21394 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1439 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1828 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 1124 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 1892 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 3977 | 0.070 |
Why?
|
| Middle Aged | 5 | 2019 | 28893 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2014 | 884 | 0.070 |
Why?
|
| Child | 3 | 2022 | 25756 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 553 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 1835 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2019 | 17345 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 897 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 898 | 0.060 |
Why?
|
| Heart Failure | 1 | 2020 | 2391 | 0.060 |
Why?
|
| Kidney | 1 | 2012 | 1326 | 0.060 |
Why?
|
| Registries | 3 | 2018 | 1588 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 2149 | 0.060 |
Why?
|
| Hypertension | 1 | 2012 | 1386 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 7113 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2021 | 695 | 0.050 |
Why?
|
| Gender Identity | 1 | 2023 | 74 | 0.050 |
Why?
|
| Nose | 1 | 2023 | 102 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 698 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6435 | 0.050 |
Why?
|
| Markov Chains | 2 | 2012 | 98 | 0.050 |
Why?
|
| Face | 1 | 2023 | 189 | 0.050 |
Why?
|
| Esthetics | 1 | 2021 | 35 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2021 | 119 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1450 | 0.040 |
Why?
|
| Epoetin Alfa | 1 | 2020 | 9 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 271 | 0.040 |
Why?
|
| Publishing | 1 | 2021 | 105 | 0.040 |
Why?
|
| Comorbidity | 2 | 2015 | 1604 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2021 | 189 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 385 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 208 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2014 | 5143 | 0.040 |
Why?
|
| Crush Injuries | 1 | 2019 | 5 | 0.040 |
Why?
|
| Degloving Injuries | 1 | 2019 | 3 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2019 | 28 | 0.040 |
Why?
|
| Hyperemia | 1 | 2019 | 35 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 101 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 2920 | 0.040 |
Why?
|
| Neoplasms | 1 | 2013 | 2953 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 74 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2018 | 32 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2018 | 34 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2018 | 140 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 363 | 0.030 |
Why?
|
| Streptokinase | 1 | 2017 | 19 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2018 | 194 | 0.030 |
Why?
|
| American Medical Association | 1 | 2016 | 7 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 3019 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 436 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2019 | 292 | 0.030 |
Why?
|
| Specialty Boards | 1 | 2016 | 24 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 121 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2016 | 59 | 0.030 |
Why?
|
| Adult | 4 | 2019 | 31506 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2017 | 182 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 18 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 207 | 0.030 |
Why?
|
| Decision Making, Organizational | 1 | 2015 | 4 | 0.030 |
Why?
|
| Economics, Medical | 1 | 2015 | 8 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 389 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 275 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2019 | 558 | 0.030 |
Why?
|
| Comprehension | 1 | 2015 | 81 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 285 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 97 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2021 | 14715 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 294 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1035 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 255 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 204 | 0.030 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2014 | 93 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 615 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 799 | 0.020 |
Why?
|
| Length of Stay | 1 | 2019 | 1379 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2014 | 206 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 2450 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1246 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1255 | 0.020 |
Why?
|
| Learning | 1 | 2015 | 370 | 0.020 |
Why?
|
| Psychometrics | 1 | 2015 | 693 | 0.020 |
Why?
|
| Catheterization | 1 | 2012 | 241 | 0.020 |
Why?
|
| Patient Participation | 1 | 2013 | 240 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 761 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 1228 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 461 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 899 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 447 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 1062 | 0.020 |
Why?
|
| Communication | 1 | 2013 | 540 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1303 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1720 | 0.020 |
Why?
|
| Animals | 2 | 2019 | 34908 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2015 | 1252 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 9929 | 0.010 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 784 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 13032 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 18534 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 20524 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 2059 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 10893 | 0.010 |
Why?
|